Opinion|Videos|January 17, 2025

A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2

Author(s)Jeff Hall

In the second part of a two-part interview on the recently published appropriate use criteria for brain positron emission tomography (PET) for patients with mild cognitive impairment (MCI), Phillip Kuo, M.D. discusses clinical cases involving the use of amyloid and tau PET imaging.

“I like to say that amyloid (PET) is necessary for the diagnosis of Alzheimer’s disease but not sufficient,” noted Phillip Kuo, M.D., during a recent interview to discuss the recently released appropriate use criteria for amyloid and tau positron emission tomography (PET) in patients with mild cognitive impairment (MCI).

Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Current Perspectives on Integrating AI into Radiology
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.